On April 5, 2019, Altiva Management Inc. announced that he has engaged in correspondence and discussions with the Progenics Pharmaceuticals, Inc.’s Board of Directors regarding important concerns and potential changes involving the Company. In connection to this, Balaji Venkataraman stated that on March 15, 2019, in accordance with the Company’s By-Laws, Velan Capital delivered to the Company a letter and certain related materials nominating 6 director candidates, including Bala Venkataraman, Virinder Nohria, Matthew Heck, Deepak Sarpangal, Ryan Melkonian, and Terence Cooke, to be considered for appointment or election to the Issuer’s Board.